Application of Spexin active polypeptide in the preparation of drugs for enhancing myocardial contractility
By using Spexin active peptide to enhance calcium transients in cardiomyocytes, it solves the malignant arrhythmia problem of traditional drugs when improving myocardial contractility, significantly improves calcium homeostasis and heart function in heart failure, and provides a new treatment method for heart failure. .
Patent Information
- Application Number
- CN202410024869.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-01-08
- Publication Date
- 2024-11-05
- Estimated Expiration
- 2044-01-08
AI Technical Summary
Traditional positive introphic drugs can easily lead to malignant arrhythmias and increase mortality when improving myocardial contractility. The existing technology has not effectively explored effective treatment methods for heart failure, especially in the case of calcium homeostasis of cardiomyocytes.
Spexin active polypeptide is used as the only active ingredient or one of the active ingredients to enhance myocardial contractility by enhancing calcium transients in cardiomyocytes. It is used for non-gastrointestinal dosage forms to treat heart failure-related diseases and complications.
It significantly improves the calcium homeostasis imbalance of cardiomyocytes during heart failure, increases cardiomyocyte contraction, improves cardiac function, and reduces mortality, providing a new and effective treatment for heart failure.
Smart Images

Figure CN117815360B_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of drugs for enhancing myocardial contractility, and in particular relates to the application of Spexin active polypeptide in the preparation of drugs for enhancing myocardial contractility. Background Art
[0002] Heart failure is the final outcome of most cardiovascular diseases and the leading cause of death. It has high disability and mortality rates and has become one of the major global public health issues. With the aging of the population, the prevalence and hospitalization rates of heart failure continue to rise. Exploring effective treatments for heart failure remains a key and difficult issue for global public health.
[0003] Myocardial contractility refers to an intrinsic property of myocardial fibers that changes their contraction strength and speed independently of foreload and afterload. When the heart rate is constant, the greater the myocardial contractility, that is, the stronger the contraction strength and the faster the contraction speed, the greater the stroke volume, and vice versa. Myocardial contractility decreases in heart failure, and the imbalance of calcium homeostasis in myocardial cells is an important mechanism. Traditional positive inotropic drugs increase myocardial contractility by increasing the concentration of calcium ions in myocardial cells, but they often cause malignant arrhythmias and even increase mortality. Therefore, finding drugs that can effectively improve cardiac contractile function and clinical symptoms in patients with heart failure and reduce hospitalization rates and the incidence of adverse events has gradually become a hot topic in clinical research.
[0004] Spexin active peptide is a new type of endogenous bioactive peptide hormone. Studies have confirmed that Spexin active peptide plays a key role in regulating physiological functions such as pain, appetite, defecation, glucose and lipid metabolism, water and salt balance, and anti-inflammation. However, there are no reports on whether Spexin active peptide is involved in the regulation of myocardial contractility. Summary of the invention
[0005] The present invention provides a new medical application of Spexin active polypeptide, namely, application of Spexin active polypeptide in preparing a drug for enhancing myocardial contractility.
[0006] The technical solution of the present invention:
[0007] Application of Spexin active polypeptide in the preparation of drugs for enhancing myocardial contractility.
[0008] Furthermore, the amino acid sequence of the Spexin active polypeptide is NWTPQAMLYLKGAQ.
[0009] Furthermore, the drug for enhancing myocardial contractility has Spexin active polypeptide as the only active ingredient or one of the active ingredients.
[0010] Furthermore, the content of Spexin active polypeptide in the drug for enhancing myocardial contractility is 0.1wt% to 99wt%.
[0011] Furthermore, the drug for enhancing myocardial contractility also includes pharmaceutically acceptable excipients and / or carriers.
[0012] Furthermore, the drug for enhancing myocardial contractility is used to enhance myocardial contractility in mammals.
[0013] Furthermore, the mammal is a human or a mouse.
[0014] Furthermore, the drug for enhancing myocardial contractility is a parenteral dosage form, specifically an injectable dosage form.
[0015] Furthermore, the drug for enhancing myocardial contractility includes drugs for treating heart failure caused by heart failure-related diseases and drugs for heart failure-related complications.
[0016] Furthermore, the heart failure-associated diseases include coronary heart disease, hypertension, valvular disease, myocarditis, cardiomyopathy, arrhythmia, metabolic disease, tumor and / or tumor treatment-related heart disease, or a combination thereof.
[0017] Furthermore, the metabolic disease includes: diabetes, dyslipidemia, thyroid disease, hyperuricemia, metabolic syndrome, or a combination thereof.
[0018] Beneficial effects of the present invention:
[0019] The present invention provides a new drug use of Spexin active polypeptide for enhancing myocardial contractility. In vitro experimental results confirm that Spexin incubation can increase calcium transients in myocardial cells and enhance the contractility of myocardial cells; animal experimental results of heart failure confirm that Spexin active polypeptide can improve calcium homeostasis imbalance of myocardial cells during heart failure, increase the contractility of myocardial cells, and improve the cardiac function and long-term survival rate of mice.
[0020] The present invention applies Spexin active polypeptide to the preparation of drugs for enhancing myocardial contractility and develops new clinical uses thereof. Since Spexin active polypeptide has a significant function of enhancing myocardial contractility, improving the cardiac function of mice with heart failure and reducing mortality, it is expected to become a new and effective treatment for preventing and treating heart failure. BRIEF DESCRIPTION OF THE DRAWINGS
[0021] Figure 1 This is a comparison of the sarcomere shortening rate of mouse cardiomyocytes before and after incubation with different concentrations of Spexin active polypeptide in Example 1;
[0022] Figure 2It is a representative picture of the contraction of mouse cardiomyocytes before and after incubation with Spexin active polypeptide in Example 1;
[0023] Figure 3 This is a comparison of the calcium transient amplitude of mouse myocardial cells before and after incubation with the Spexin active polypeptide in Example 1;
[0024] Figure 4 This is a schematic diagram comparing the time distribution of calcium transients in mouse myocardial cells before and after incubation with the Spexin active polypeptide in Example 1;
[0025] Figure 5 This is a comparison of the amplitudes of calcium transients in myocardial cells of each group of mice in Example 2;
[0026] Figure 6 This is a comparison diagram of the calcium transient time distribution of myocardial cells in each group of mice in Example 2;
[0027] Figure 7 This is a comparison of the time constants of calcium decline in myocardial cells of each group of mice in Example 2;
[0028] Figure 8 These are representative pictures of Fluo-3 staining of myocardial cells of each group of mice in Example 2;
[0029] Fig. 9 This is a comparison of the resting calcium levels of myocardial cells in each group of mice in Example 2;
[0030] Fig.10 These are representative images of cardiac ultrasound detection of each group of mice in Example 2;
[0031] Fig.11 This is a comparison chart of the LVEF test results of each group of mice in Example 2;
[0032] Fig.12 This is a comparison chart of the LVFS test results of each group of mice in Example 2;
[0033] Fig.13 This is a comparison chart of the survival curves of each group of mice in Example 2. DETAILED DESCRIPTION
[0034] The technical solution of the present invention is further described below in conjunction with the embodiments, but it is not limited thereto. Any modification or equivalent replacement of the technical solution of the present invention without departing from the spirit and scope of the technical solution of the present invention shall be included in the protection scope of the present invention. The process equipment or devices not specifically noted in the following embodiments are all conventional equipment or devices in the art. If not specifically specified, the raw materials used in the embodiments of the present invention can be obtained commercially; if not specifically specified, the technical means used in the embodiments of the present invention are all conventional means well known to those skilled in the art.
[0035] Example 1
[0036] This example investigates the effect of Spexin active polypeptide on the contraction of mouse cardiomyocytes.
[0037] Spexin active peptide was administered to incubate cardiomyocytes. The specific method was as follows:
[0038] 1. Isolation of adult mouse cardiomyocytes: Adult C57BL / 6 mice were anesthetized by intraperitoneal injection of 0.1 mL heparin (150 mg / ml), and the heart was quickly isolated and placed in a 4°C precooled calcium-containing benchtop solution. The aorta root was suspended and connected to a Langendorff perfusion device, and perfused with calcium-free perfusion solution at 37°C. Calcium-free benchtop solution containing BSA (0.75 mg / ml) and type II collagenase (1 mg / ml) was added. The heart was removed, the ventricular part was cut off, and the ventricle was gently cut and blown in a calcium-containing benchtop solution containing CaCl2 (200 μM) and BSA (1%), and filtered through a filter. The filtrate was the cardiomyocyte suspension.
[0039] 2. Determination of myocardial cell contractility: Pipette a small amount of cell suspension and place it in a cell perfusion tank, perfuse it with oxygen-containing calcium-containing benchtop solution, and give myocardial cells an electric field stimulation with a constant frequency and voltage of 1Hz. Record and measure the changes in the length of myocardial cell sarcomeres, that is, the changes in the length of a single myocardial cell during relaxation and contraction.
[0040] 3. Determination of calcium transient in myocardial cells: Incubate myocardial cells with Fluo-3 and rinse with calcium-containing benchtop solution three times. Take a small amount of cell suspension and place it in the cell perfusion tank, and give electric field stimulation at a constant frequency of 1Hz. The fluorescence intensity of the cells reflects the changes in calcium in myocardial cells, and the amplitude of calcium transient in myocardial cells is calculated.
[0041] 4. Determination of resting calcium in cardiomyocytes: Wash the cardiomyocytes stained with Fluo-3 using calcium-free benchtop solution, and determine the resting calcium in cardiomyocytes using a confocal microscope. Image J is used to count the fluorescence values of individual cardiomyocytes, which represent the intracellular calcium content.
[0042] 5. Spexin incubation concentration: Incubate the cardiomyocytes in the cell perfusion tank with 10, 100 and 1000 nM Spexin active polypeptide, respectively. Detect the contractile force and calcium transient amplitude of the cardiomyocytes before and immediately after the incubation with Spexin active polypeptide, respectively. The number of detected cardiomyocytes shall be no less than 15.
[0043] Figure 1 This is a comparison of the sarcomere shortening rate of mouse cardiomyocytes before and after incubation with different concentrations of Spexin active peptide; Figure 2 The representative pictures are of the contraction of mouse cardiomyocytes before and after incubation with Spexin active peptide; Figure 1 , Figure 2As shown in the results, the myometrial shortening of cardiomyocytes incubated with Spexin active peptide was significantly increased compared with that before incubation, and further studies found that 10, 100 and 1000 nM of Spexin active peptide could increase myometrial shortening in a dose-dependent manner. This indicates that Spexin active peptide can enhance the contractility of cardiomyocytes.
[0044] Figure 3 This is a comparison of the calcium transient amplitude of mouse cardiomyocytes before and after incubation with Spexin active peptide; Figure 4 This is a schematic diagram comparing the time distribution of calcium transients in mouse myocardial cells before and after incubation with Spexin active polypeptide; Figure 3 , Figure 4 As shown, 1000nM Spexin active peptide was given to incubate cardiomyocytes in the perfusion tank, and the changes before and after Spexin active peptide incubation were observed. The changes in fluorescence intensity in the cells indicated the changes in intracellular calcium content. The results showed that after myocardial cells were incubated with Spexin active peptide, the intracellular Ca 2+ The maximum value of the change was significantly increased compared to before incubation. It can be seen that Spexin active polypeptide increased the calcium transient of mouse cardiomyocytes after incubation, which indicates that Spexin active polypeptide can enhance the contractility of cardiomyocytes by increasing calcium transient in cardiomyocytes.
[0045] Example 2
[0046] This example investigates the effect of Spexin active polypeptide on calcium homeostasis in myocardial cells of mice with heart failure.
[0047] The experimental animals used in the present invention were all 8-10 week old male adult C57BL / 6 mice, weighing 22-25 g, purchased from Weitonglihua Experimental Animal Technology Co., Ltd.
[0048] Modeling, grouping, and drug administration methods:
[0049] Establishment of TAC-aortic arch constriction-induced chronic heart failure mouse model: After intraperitoneal injection of aflototin (0.2 g / kg) for anesthesia, mice were intubated and connected to a ventilator. The surgical area was depilated, and an opening was made from the suprasternal fossa downward to the second rib. A 6-0 silk thread was placed in the aortic arch between the brachiocephalic trunk and the left common carotid artery. A knot was tied around the aortic arch while a 27G flat-head needle was placed parallel to the aortic arch. The flat-head needle was removed and the chest cavity was closed. The sham group was the same as the TAC group except for the ligation procedure.
[0050] The mice were divided into sham operation group, heart failure group and Spexin active peptide treatment group, which were marked as Sham group, TAC group and TAC+SPX group respectively. Each group of mice was intraperitoneally injected with 0.1 ml of normal saline or Spexin on the day of surgery. The dosage of Spexin active peptide was 70 μg / kg per day. The model and treatment lasted for 8 weeks.
[0051] The myocardial cells of each group of mice were separated, and the calcium transient and resting calcium levels of the myocardial cells of each group were detected respectively. The experimental method was the same as that of Example 1.
[0052] Figure 5 Comparison of calcium transient amplitudes in myocardial cells of mice in each group; Figure 6 The comparison diagram of calcium transient time distribution of myocardial cells in each group of mice; Figure 5 and Figure 6 The results showed that compared with the Sham group, the amplitude of calcium transient in the cardiomyocytes of the mice in the TAC group was reduced, and compared with the TAC group, the amplitude of calcium transient in the cardiomyocytes of the mice in the TAC+SPX group was significantly increased.
[0053] Figure 7 This is a comparison of the time constants of calcium decrease in myocardial cells of each group of mice; Figure 7 The results showed that compared with the Sham group, the decrease time of intracardiac calcium in the myocardial cells of the mice in the TAC group was prolonged, and compared with the TAC group, the decrease time of intracardiac calcium in the myocardial cells of the mice in the TAC+SPX group was significantly shortened.
[0054] Figure 8 Representative pictures of Fluo-3 staining of cardiomyocytes of mice in each group; Fig. 9 The comparison chart of resting calcium level of cardiomyocytes in each group of mice; Figure 8 , Fig. 9 The results showed that compared with the Sham group, the resting calcium level of cardiomyocytes of mice in the TAC group was increased, and compared with the TAC group, the resting calcium level of cardiomyocytes of mice in the TAC+SPX group was significantly decreased.
[0055] Fig.10 Representative images of cardiac ultrasound detection of mice in each group. Fig.11 The comparison chart of LVEF test results of each group of mice. Fig.12 The comparison chart of LVFS test results of each group of mice. Fig.13 The comparison chart of the survival curves of mice in each group; Figures 10 to 13 The results showed that compared with the Sham group, the LVEF and LVFS of TAC mice were decreased, indicating a decrease in cardiac contractile function; exogenous supplementation of Spexin restored the LVEF and LVFS of mice and reduced the mortality rate.
[0056] The above experimental results confirm that Spexin active peptide can enhance the contractility of cardiomyocytes, increase intracellular calcium in cardiomyocytes, alleviate the imbalance of calcium homeostasis in cardiomyocytes in chronic heart failure, improve cardiac contractile function, and thus improve the prognosis of mice with heart failure. It is expected to become a safe and effective drug for the prevention and treatment of heart failure.
Claims
1. Application of Spexin active peptide in the preparation of drugs for chronic heart failure caused by pressure overload, It is characterized in that The amino acid sequence of the Spexin active polypeptide is NWTPQAMLYLKGAQ.
2. Use of the Spexin active polypeptide according to claim 1 in the preparation of a medicament for chronic heart failure caused by pressure overload, It is characterized in that The drug uses Spexin active polypeptide as the only active ingredient or one of the active ingredients.
3. Use of the Spexin active polypeptide according to claim 2 in the preparation of a medicament for chronic heart failure caused by pressure overload, It is characterized in that The content of Spexin active polypeptide in the medicine is 0.1wt%~99wt%.
4. Use of the Spexin active polypeptide according to claim 3 in the preparation of a medicament for chronic heart failure caused by pressure overload, It is characterized in that The drug also includes pharmaceutically acceptable excipients and / or carriers.
5. Use of the Spexin active polypeptide according to claim 4 in the preparation of a medicament for chronic heart failure caused by pressure overload, It is characterized in that The drug is used to enhance the contractility of the myocardium of a mammal.
6. Use of the Spexin active polypeptide according to claim 5 in the preparation of a medicament for chronic heart failure caused by pressure overload, It is characterized in that The drug is a parenteral dosage form, specifically an injection dosage form.
Citation Information
Cited By
Application of Spexin active polypeptide in preparation of medicine for preventing and treating ischemia-reperfusion ventricular arrhythmia
CN120053597A
